Coya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Coya Therapeutics (NASDAQ:COYA) with a target price of $18.00, indicating a potential upside of 192.64% from its previous close.
• Despite the positive ratings from several research firms, Coya's stock reported disappointing earnings, with an EPS loss of ($0.36) missing analyst estimates by ($0.14).
• Institutional investors are showing increased interest in Coya Therapeutics, with 39.75% of the company's stock now owned by hedge funds and other institutions.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $18.00 target price on the stock. D. Boral Capital's price target indicates a potential upside of 192.64% from the stock's previous close.

Several other research firms have also recently weighed in on COYA. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, June 9th. Wall Street Zen cut Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Lake Street Capital began coverage on Coya Therapeutics in a report on Wednesday, July 9th. They set a "buy" rating and a $16.00 price objective on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Wednesday. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Coya Therapeutics has an average rating of "Moderate Buy" and an average target price of $16.50.

Coya Therapeutics Stock Up 0.3%

NASDAQ COYA traded up $0.02 during trading hours on Wednesday, reaching $6.15. The company's stock had a trading volume of 10,841 shares, compared to its average volume of 73,932. The firm's 50-day moving average price is $5.95 and its 200-day moving average price is $6.08. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $10.24. The company has a market capitalization of $102.91 million, a price-to-earnings ratio of -5.65 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. Equities research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its holdings in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after buying an additional 4,777 shares during the period. XTX Topco Ltd purchased a new stake in Coya Therapeutics in the fourth quarter worth $59,000. Charles Schwab Investment Management Inc. purchased a new stake in Coya Therapeutics in the first quarter worth $65,000. Jane Street Group LLC purchased a new stake in Coya Therapeutics in the fourth quarter worth $74,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in Coya Therapeutics in the second quarter worth $119,000. Hedge funds and other institutional investors own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.